nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

17.02.2016 | Editorial

Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer

verfasst von: Frederik A. Verburg, Cumali Aktolun, Arturo Chiti, Savvas Frangos, Luca Giovanella, Martha Hoffmann, Ioannis Iakovou, Jasna Mihailovic, Bernd J. Krause, Werner Langsteger, Markus Luster, on behalf of the EANM and the EANM Thyroid Committee

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Excerpt

Recently the American Thyroid Association (ATA) released the third version of one of the most cited differentiated thyroid cancer (DTC) guidelines under the title “2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer” [1]. Compared to the earlier versions [2, 3], these guidelines are a major departure, as the volume of the text, the number of recommendations and the number of references have increased considerably. …

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.CrossRefPubMed

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–42.CrossRefPubMed

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRefPubMed

Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.CrossRefPubMed

Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59.CrossRefPubMed

Gharib H, Papini E, Valcavi R, Baskin HJ, Crescenzi A, Dottorini ME, et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2006;12:63–102.CrossRefPubMed

Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v214–9.CrossRefPubMed

Treglia G, Trimboli P, Verburg FA, Luster M, Giovanella L. Prevalence of normal TSH value among patients with autonomously functioning thyroid nodule. Eur J Clin Invest. 2015;45:739–44.CrossRefPubMed

Chami R, Moreno-Reyes R, Corvilain B. TSH measurement is not an appropriate screening test for autonomous functioning thyroid nodules: a retrospective study of 368 patients. Eur J Endocrinol. 2014;170:593–9.CrossRefPubMed

10.

Hurtado-Lopez LM, Monroy-Lozano BE, Martinez-Duncker C. TSH alone is not sufficient to exclude all patients with a functioning thyroid nodule from undergoing testing to exclude thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1173–8.CrossRefPubMed

11.

Ianni F, Perotti G, Prete A, Paragliola RM, Ricciato MP, Carrozza C, et al. Thyroid scintigraphy: an old tool is still the gold standard for an effective diagnosis of autonomously functioning thyroid nodules. J Endocrinol Investig. 2013;36:233–6.

12.

Schicha H, Hellmich M, Lehmacher W, Eschner W, Schmidt M, Kobe C, et al. Should all patients with thyroid nodules > or = 1 cm undergo fine-needle aspiration biopsy? Nuklearmedizin. 2009;48:79–83.PubMed

13.

Giovanella L, Suriano S, Maffioli M, Ceriani L, Spriano G. (99m)Tc-sestamibi scanning in thyroid nodules with nondiagnostic cytology. Head Neck. 2010;32:607–11.PubMed

14.

Giovanella L, Campenni A, Treglia G, Verburg FA, Trimboli P, Ceriani L, et al. Molecular imaging with 99mTc-MIBI and molecular testing for mutations in differentiating benign from malignant follicular neoplasm: a prospective comparison. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-015-3285-1

15.

Heinzel A, Muller D, Behrendt FF, Giovanella L, Mottaghy FM, Verburg FA. Thyroid nodules with indeterminate cytology: molecular imaging with (99m)Tc-methoxyisobutylisonitrile (MIBI) is more cost-effective than the Afirma gene expression classifier. Eur J Nucl Med Mol Imaging. 2014;41:1497–500.CrossRefPubMed

16.

Wale A, Miles KA, Young B, Zammit C, Williams A, Quin J, et al. Combined (99m)Tc-methoxyisobutylisonitrile scintigraphy and fine-needle aspiration cytology offers an accurate and potentially cost-effective investigative strategy for the assessment of solitary or dominant thyroid nodules. Eur J Nucl Med Mol Imaging. 2014;41:105–15.CrossRefPubMed

17.

Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008;37:457–80.CrossRefPubMed

18.

Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.CrossRefPubMed

19.

Mallick U, Harmer C, Hackshaw A, Moss L. Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clin Oncol (R Coll Radiol). 2012;24:159–61.CrossRef

20.

Verburg FA, Mader U, Reiners C, Hanscheid H. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical (131)I therapy in both high- and low-risk patients. J Clin Endocrinol Metab. 2014;99:4487–96.CrossRefPubMed

21.

Frangos S, Iakovou IP, Marlowe RJ, Eftychiou N, Patsali L, Vanezi A, et al. Difficulties in deciding whether to ablate patients with putatively “low-intermediate-risk” differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study. Eur J Nucl Med Mol Imaging. 2015;42:2045–55.CrossRefPubMed

22.

Hanscheid H, Verburg FA, Biko J, Diessl S, Demidchik YE, Drozd V, et al. Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level. Eur J Nucl Med Mol Imaging. 2011;38:1296–302.CrossRefPubMed

23.

Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–32.CrossRefPubMed

24.

Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877–85.PubMed

25.

Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009;94:4171–9.CrossRefPubMed

26.

Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–73.CrossRefPubMed

27.

Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674–85.CrossRefPubMed

28.

Borget I, Bonastre J, Catargi B, Deandreis D, Zerdoud S, Rusu D, et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial. J Clin Oncol. 2015;33(26):2885–92.CrossRefPubMed

29.

Bartenstein P, Calabuig EC, Maini CL, Mazzarotto R, Muros de Fuentes MA, Petrich T, et al. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Thyroid. 2014;24:480–7.CrossRefPubMed

30.

Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab. 2011;96:2105–11.CrossRefPubMed

31.

Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613–9.CrossRefPubMed

32.

Dow KH, Ferrell BR, Anello C. Balancing demands of cancer surveillance among survivors of thyroid cancer. Cancer Pract. 1997;5:289–95.PubMed

Titel: Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer
verfasst von: Frederik A. Verburg
Cumali Aktolun
Arturo Chiti
Savvas Frangos
Luca Giovanella
Martha Hoffmann
Ioannis Iakovou
Jasna Mihailovic
Bernd J. Krause
Werner Langsteger
Markus Luster
on behalf of the EANM and the EANM Thyroid Committee
Publikationsdatum: 17.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3327-3

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

The Pathophysiologic Basis of Nuclear Medicine, Third Edition, Abdelhamid H. Elgazzar, Ed.

Metabotropic glutamate receptor 5 – a promising target in drug development and neuroimaging

Evaluation of 124I PET/CT and 124I PET/MRI in the management of patients with differentiated thyroid cancer

Tau imaging in neurodegenerative diseases

18F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma

Reproducibility of O-(2-18F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas